Merck boasts bone drug trials show "robust efficacy"
July 12 2012
Merck announced it was halting Phase III trials of its experimental osteoporosis drug odanacatib because the data monitoring committee's interim ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.